Contact Us
Saturday, 17 November 2018
Subscribe to newsletter

"Biotechnology and the industries it will enable in the future are a key part of Queensland's economic prosperity. Agriculture, energy and mining, biomedical, environmental and industrial sectors all to some extent will draw on the innovative potential of biotechnology. Life Sciences Queensland will bring together the relevant players to make a contribution to the diversification and strengthening of Queensland and Australia's future"

Dr Peter Riddles - Inaugural Chairman

LSQ is an opportunity for industry stakeholders to come together and cooperate to grow their businesses and help create a dynamic, internationally competitive and sustainable life sciences industry in Queensland, Australia. LSQ is helping to shape the strategic direction of the industry in the State and influence public policy. We also provide members with tools, services, market intelligence and access to an international network of life sciences organisations with the aim of identifying new business opportunities and accelerating business growth.

In a broader sense, LSQ is working to enhance Queensland’s national and international reputation as a centre of commercial and research excellence in life sciences. LSQ is an industry-led vehicle, which promotes and supports all segments of the Queensland life sciences industry.

LSQ engages the full spectrum of the Queensland life sciences industry, to assist the growth of individual organisations and industry segments, and to build the profile, capacity and capability of the sector to help ensure long term economic, social and environmental benefits to Queensland and its members. The primary objectives of LSQ are to: 
  • Develop the industry by supporting local industry forums and providing members with tools to accelerate their business growth.
  • Create new business opportunities for members through market outreach (e.g. business development services, event management, a co-ordinated approach to international business meetings) that members cannot readily or cost-effectively achieve on their own.  
  • Play a leading role in influencing public policy so as to help ensure sustainable growth of the Queensland Life Science Industry.

Sub-sectors that are illustrative of the Australian life science industry include:

  • Human Healthcare (pharmaceuticals or drug discovery, complementary medicines, functional foods/beverages, medical devices and diagnostics),
  • Animal Health,
  • Agricultural and Environmental Biotechnology,
  • Marine Biotechnology and
  • Industrial Biotechnology, including Bio-mining and Bio-energy.
LSQ Board
  Prof Peter Andrews AO - Chairman

Professor Andrews served as Queensland's first Chief Scientist from 2003 to 2010. Before that, he led multidisciplinary scientific teams in several Australian universities and co-founded six biotechnology companies, two of which took drugs to global markets.
He is the co-author, with social scientist Dr Fiona Wood, of "Überpreneurs: how to create innovative global businesses and transform human societies", published in 2014. 

He is currently chairman of the boards of Implicit Bioscience Ltd, Vast Bioscience Pty Ltd and QUTbluebox Pty Ltd, and of the scientific advisory boards of Bond University Faculty of Health Sciences and Medicine and the Maurice Wilkins Centre for Molecular Biodiscovery (NZ).

Jennifer Barker - EY  

Jennifer is an Assurance Director in EY’s Brisbane office and has over fourteen years’ experience in auditing a variety of industries and corporate reporting requirements in Australia and the United States. Jennifer joined EY in 2002 in the Raleigh USA office and then transferred to the Brisbane office in 2006.

She has had a broad range of experience serving clients in a variety of industries including waste management, pharmaceutical, technology, and diversified products.

 Kathy Connell - Johnson & Johnson Innovation

Kathy is Director of New Ventures, Australia and New Zealand (ANZ) for Johnson & Johnson Innovation, Asia-Pacific and is responsible for implementing our strategy across Australia and New Zealand. Kathy has a clinical background and started her commercial career as the VP of Global Business Development for an Australian biotechnology company. Prior to joining Janssen, Kathy worked for Sanofi engaged in in-licensing late stage pharmaceutical assets. Kathy joined Janssen as Biotechnology Alliance Manager in 2011.
Kathy is a registered psychologist and holds Post Graduate Diplomas in Health and Medical Law from the University of Melbourne, Psychology from Monash University and Bachelor degrees in Psychology (Swinburne University) and Applied Science from LaTrobe University. She is based in Sydney Australia.

 Dr Peter Devine - UniSeed

Peter has been CEO of Uniseed since 2006, taking on management of Uniseed’s second fund of $40 million, which provided a number of high profile exits including Spinifex Pharmaceuticals acquisition by Novartis for US$200M up‐front plus milestone payments; Fibrotech Therapeutics sale to Shire plc for US$75M up‐front plus milestone payments, and Hatchtech’s sale to Dr Reddy’s Laboratories in a deal worth $200M. Uniseed started its third fund in March 2016 – a $50 million partnership between the Universities of Queensland, NSW, Sydney and Melbourne, and the CSIRO. A $20 million follow-on fund was also announced in early 2017.
Peter has extensive experience at board and executive management levels in the commercialisation of early stage technologies, having held senior R&D, business development and commercialisation positions in a number of Australian companies and Australian universities.
Peter was VP of Business Development at ASX-listed Progen Industries Ltd. He was Research, Development and Commercialisation Manager at Brisbane-based PanBio Pty Ltd from 1996 to 2000, which ultimately was sold to Inverness Medical.
Peter had a distinguished career in academic research, being the recipient of a number of competitive grants, which resulted in numerous patents, publications and scientific presentations at conferences. Received the Dean's Prize and the AGSM Alumni Scholarship for his MBA Studies at the Australian Graduate School of Management. Received a Centenary Medal in 2003 for outstanding contribution to the business of biotechnology.
Peter is a Graduate and Fellow of the Australian Institute of Company Directors and holds a Diploma of Financial Services (Financial Markets) and a Graduate Diploma in Applied Finance from Kaplan Professional. In 2011 & 2012, Peter was named on the Kaplan High Achievers Honour Roll.

 James Macnaughtan - Cook Medical

James has had over 35 years in the medical device arena with experience in sales, marketing, new product development and manufacturing operations. He had close involvement with the development of the Zenith Endovascular Graft, working with the both Australia clinical inventors of this device from Perth as well as global clinical leaders in endovascular aortic repair. This immensely successful range of devices became the basis of Cook’s Aortic Intervention business unit and is recognised internationally as a benchmark technology for endovascular treatment of aortic aneurysms. 
After guiding expansion of the Zenith graft into Asia, in particular Japan and China for 7 years, James then headed the Surgery business unit’s expansion and growth into APAC. As Director New Technologies APAC, he now leads the Asia-Pacific New Technology Team - ANTT - which has seen a number of new technologies introduced to Cook Medical from the region since its inception in early 2014.
James was appointed to the board of William A Cook Australia Pty Ltd in June 1987 and to the board of Life Sciences Queensland in August 2015.


Michael McArdle - Queensland University of Technology (QUT)

Michael McArdle has worked in the field of university administration for 20 years, of which the last 15 years have been dedicated to research and research training management. He held a number of positions at The University of Queensland over a 9 year period, including Theses Officer, Research Administration Officer and Research Unit Coordinator, within the Office of Research and Postgraduate Studies, before joining Queensland University of Technology in 2000 as Head, Research Development within the Office of Research. In 2003, he took on the role of Acting Manager of the Office of Research and was formally appointed as Director in 2005. As Director he oversees 5 business units covering research development, ethics, finance, data and research quality. 

 Professor Brandon Wainwright - Institute for Molecular Bioscience

Professor Brandon Wainwright was appointed Director of the Institute for Molecular Bioscience in early 2006. Previously, he was the Deputy Director (Research) of the IMB from 2002. 
Professor Wainwright’s major research focus is in tissue repair and cancer.  He led the team responsible for finding the origins of the often-fatal brain tumour, medulloblastoma, and the most common form of cancer, basal cell carcinoma of the skin. Through the mapping and isolation of the genes responsible for these diseases, his group has continued to follow through on each to understand how the genetic defects lead to the disease. 

Professor Wainwright is committed to translating  high quality research into outcomes and his own research has been supported by a number of Biotech companies including the global biopharmaceutical companies AMGEN and Genentech (now Roche).

LSQ Management

  Mr. Mario Pennisi - Chief Executive Officer
Mario Pennisi is the inaugural CEO of LSQ. He has been the CEO of QCTN since its establishment in 2005, and has over 20 years experience in the life sciences industry. Mario has extensive experience in managing commercial operations in the life science industry. In the mid 1990s, in affiliation with US and German-based organisations, he established the first Queensland-based ‘central laboratory’, servicing international trials in the Asia-Pacific region. He was also a founding member of Queensland’s first contract research organisation.
Mario has overseen QCTN’s growth to become Australia’s peak industry group for therapeutic product service providers. QCTN represents over 100 members and it maintains relationships with strategic partners across the Asia Pacific Region and in Europe and North America.

  Mrs. Clare Blain - Chief Operating Officer
Clare Blain (née Schodel) had worked with QCTN for four years prior to transitioning into Life Sciences Queensland. Initially starting at QCTN in 2007 as Marketing Coordinator, her role developed over time from Marketing Manager to Operations Manager today. Clare has over 13 year’s experience working not only in the communications and marketing field, but also working with membership organisations.
Lachlan Storie 

Lachlan Storie - Marketing + Communications Coordinator
Lachlan Storie joined LSQ late in 2015, previously working in membership for the Queensland Reds. He holds a Bachelor of Business Management (UQ) and has a comprehensive background in agriculture, hailing from rural NSW. Lachlan leads  the coordination of marketing and events, in addition to the implementation of corporate communications.

   LSQ Constitution available here.